Requiring Transparency and Value-Based Care in the Pharmaceutical Industry: John O'Brien, National Pharmaceutical Council

·48 min·3 clips

O'Brien says he does not think Medicare price negotiation is a real negotiation and worries it could threaten innovation.

Aaron Strout opens the episode by framing Real Chemistry as a place where healthcare innovation, AI, and new ideas run straight into the friction of old systems. Jim Weiss then steps in as guest host for a conversation with Dr. John O’Brien, the CEO and president of the National Pharmaceutical Council. The discussion begins with what NPC does and why its 70th anniversary matters. It is a long institutional story. O’Brien and Weiss move from there into the pressure points around drug pricing, transparency, and value assessment, using those topics to show how health policy shapes what patients actually experience. The conversation draws a clear line from broad industry history to the ordinary moment at the pharmacy register. O’Brien describes learning early in his career that the medicine a person receives often depends more on the insurance card in their wallet than on the prescription itself. That idea becomes the episode’s practical anchor. The discussion explains how deductibles, benefit design, and shifting drug coverage have changed what patients pay, and how little many people understand about the money moving through the system. It never settles into a dry policy lecture. Instead, it works like a guided tour through a system that has become more confusing and, in some ways, more hostile over time. Weiss presses on how that hostility developed. O’Brien answers by linking present-day frustration to long-running changes in benefits and cost-sharing. He also frames the issue as something that cuts across party lines, from Democrats in New York to conservatives in the Villages, really anyone who has to fill a prescription. The episode then turns toward NPC’s role in helping build better evidence for value assessment. O’Brien talks about hiring Dr. John Campbell, whose background in health economics and outcomes research fits that mission and whose recent work at ICER makes him a strong addition to the team. That choice signals both continuity with the organization’s past and a push toward more evidence-centered work going forward. There is also discussion of HTA, government, and employer decision-making. The tone stays warm and conversational even when the subject matter gets technical. Jim Weiss keeps the interview moving with context, paraphrase, and the kind of soft segue that invites a fuller answer. The exchange makes room for both public policy and human stakes. That balance is one of the episode’s strengths. It stays fluent in healthcare business language without losing sight of patients. The closing stretch lightens the mood with a joke about Bruce Springsteen, a delayed tour, and the pharmaceutical work that helps people get back on the road. The ending gives the conversation a small but fitting human finish. Across the full episode, the throughline is straightforward: value-based care only matters if the system can explain value clearly enough for patients, employers, and policymakers to act on it.

As heard by us

A policy conversation that ties drug pricing, value, and the pharmacy counter to everyday coverage decisions.

The Real Chemistry Podcast turns a policy conversation into something grounded in ordinary pharmacy-counter realities, showing how drug pricing, deductibles, and value assessments shape what people are asked to pay and what they actually receive.

Read the full review in PlayNext →

Why you'd press play

Hear how drug pricing turns into the bill you see at the pharmacy.

Read the full recommendation in PlayNext →

Listen to the show on

Apple Podcasts Spotify

Play clips from this episode More from The Real Chemistry Podcast